CAM
KALA icon

Cormorant Asset Management’s KALA BIO KALA Stock Holding History

Cormorant Asset Management’s Portfolio KALA Stock Details KALA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,061
Closed -$2.87M – 38
2025
Q2 		$2.87M Hold
12,061
– – 0.21% 40
2025
Q1 		$3.46M Hold
12,061
– – 0.26% 42
2024
Q4 		$4.19M Buy
+12,061
New +$3.8M 0.23% 39

Other funds holding KALA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Cormorant Asset Management's KALA Position: Q3 2025 in Review

Cormorant Asset Management sold out of KALA BIO (KALA) in Q3 2025, closing a stake of 12,061 shares — an estimated $2.87M sold.

Cormorant Asset Management first reported a position in KALA in Q4 2024 and held it in 3 quarters. The position peaked at $4.19M in Q4 2024. 22 funds tracked by Wall St. Rank hold KALA as of Q3 2025.

  • Cormorant Asset Management reported no remaining KALA BIO position as of Q3 2025 after selling out during the quarter.
  • Cormorant Asset Management sold 12,061 KALA BIO shares in Q3 2025, an estimated $2.87M.
  • Cormorant Asset Management first reported a position in KALA BIO in Q4 2024 and held it in 3 quarters.
  • Cormorant Asset Management's KALA BIO position peaked at $4.19M in Q4 2024.
  • 22 funds tracked by Wall St. Rank held KALA BIO as of Q3 2025.

Based on Cormorant Asset Management's 13F filing for Q3 2025, filed 14 Nov 2025.